Lantheus’ (LNTH) Hold Rating Reiterated at JonesTrading

Lantheus (NASDAQ:LNTH)‘s stock had its “hold” rating restated by investment analysts at JonesTrading in a research note issued on Friday,Benzinga reports.

A number of other equities research analysts have also issued reports on the company. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Tuesday. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Citizens Jmp raised their target price on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday. William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday. Finally, Mizuho upped their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $78.83.

Lantheus Stock Performance

Shares of LNTH opened at $75.43 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The firm’s 50 day moving average is $67.97 and its 200-day moving average is $60.01. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29. The stock has a market capitalization of $5.00 billion, a P/E ratio of 31.69 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period last year, the firm posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts anticipate that Lantheus will post 6.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of hedge funds have recently modified their holdings of the stock. M&T Bank Corp purchased a new position in Lantheus in the fourth quarter valued at about $370,950,000. Farallon Capital Management LLC grew its stake in shares of Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Lantheus in the third quarter worth approximately $65,654,000. Norges Bank acquired a new position in Lantheus in the fourth quarter worth approximately $76,197,000. Finally, Polaris Capital Management LLC bought a new position in Lantheus during the third quarter valued at approximately $32,687,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results materially beat consensus: reported EPS $1.67 vs. $1.17 expected and revenue $406.8M vs. $367.0M expected; margins and ROE were strong, signalling healthy profitability and execution. Lantheus Q4 results and call
• Positive Sentiment: Analyst upgrade: William Blair raised LNTH from Market Perform to Outperform, which can support buying interest and institutional demand. William Blair upgrade
• Positive Sentiment: Price target increase: Citizens Jmp raised its target to $78, which can reinforce the bullish narrative among some investors. Price target raise
• Neutral Sentiment: Earnings call materials and transcripts are available for investors to review management’s commentary and details behind the beat. These provide color but are not new headline news. Earnings call transcript Earnings presentation
• Negative Sentiment: FY‑2026 guidance was modestly conservative: management gave EPS guidance of $5.00–$5.25 (consensus ~$5.16) and revenue guidance roughly $1.4–$1.5B (consensus ~$1.5B). The EPS range is below some analyst expectations (street average cited ~6.01 in background notes), which could cap upside. Company press release with guidance

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.